StemCell Therapy

Community Functions

Our director, Dr. Dandonas pioneering work in the diabetic center lead to his appointment as an advisor to Independent Health, Blue Cross, Blue Shield and to Community Blue in matters related to diabetes. Weve authored algorithms in diabetic management, which we disseminated to primary care physicians so that care of diabetes can be improved and its complications prevented.

Various community programs have been set up by the Center for the city, which include: Public health surveys which screens for hypercholesterolemia, diabetes, hypothyroidism and hypertension starting in 1995 and then annually thereafter. Data from initial surveys have shown us for the first time that 2/3 of Buffalos population has hypercholesterolemia (high cholesterol) and that the prevalence of diabetes in the region is eight percent. So far 9500 Western New Yorkers have been surveyed. Every year we do our best to raise funds for this activity which amounts to $45,000-50,000. These screenings are done in association with the Erie County Health Dept.

A unique Diabetes Patients Forum which meets every two months, since October 1996, which aims to empower and educate diabetic patients and their families. This forum aims to educate patients and their families regarding their conditions and empower them to ask questions regarding the management of their disease.

Endocrinology Diary for 2013

May: 2013

American College of Endocrinology and American Association of Clinical Endocrinologists, Phoenix, AZ This meeting was held in early May and one of the 10 chosen oral presentations was the one on the beneficial effects of testosterone in patients with hypogonadotropic hypogonadism. This led to a press release. Several abstracts based on clinical cases were presented by the fellows. These unique cases also raised a lot of interest.

Dr. Dandona participated in global consultants meeting related to the new anti-diabetic drug, TAK-875, from Takeda Pharmaceuticals in London, UK. This new class of drugs binds to a fatty acid receptor on the -cell in the pancreatic islet and induces the release of insulin. The fall in HbA1c is just under 1% and there is no risk of hypoglycemia. Dr Prabhakar Viswanathan, Senior Medical Director in Takeda, is leading the program to develop this drug. Dr Viswanathan is an ex-fellow from our research program from UB. He is the third fellow trained by Dr Dandona to hold such a senior position in a major pharmaceutical company. Drs Davinder (Dave) Gill and Jaswinder (Jaz) Gill (Sanofi-Aventis) are the other two.

June: 2013

Department of Medicine Research Day This day witnessed an outstanding performance by our division with the prizes for the best research and best case presentation being awarded to Manav Batra and Cherie Vaz.

Immunometabolism Symposium, Toronto Dr Dandona attended this meeting and contributed to the discussions during this meeting in relation to our groups large body of work linking metabolic states and macronutrient intake to oxidative stress and inflammation.

ADA meeting: Chicago IL

Abstracts on Research

Endocrine Society, San Francisco

Abstracts Presented with oral presentation

Our paper on effects of liraglutide in obese patients with type 1 diabetes is published online in Endocrine Practice. http://aace.metapress.com/content/76j38670g836wj7q/?p=3fd984e2fdd447458c5a69c2af65e691&pi=0

The new batch of Fellows joined. Dr Dandona was invited to be a member of the Special Programs Group of the Endocrine Society. Our paper linking obesity with asthma through an increased expression of asthma related genes in obesity was published in the journal, OBESITY.

See the rest here:
Diabetes Endocrinology Center of WNY

This entry was posted on August 4, 2016 at 9:36 am and is filed under Endocrinology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |